A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients.
Sponsor: Hoffmann-La Roche
Listed as NCT00089492, this PHASE2 trial focuses on HIV Infections and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 6 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
- Trimeris
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Allentown, United States, Atlanta, United States, Austin, United States, Boston, United States, Bradenton, United States, Denver, United States, Detroit, United States, Fountain Valley, United States, Hobson City, United States and 13 more location s